Atea Pharmaceuticals reports Phase 3 hepatitis C success and secures $200 million credit facility
Atea Pharmaceuticals announced that its Phase 3 C‑BEYOND trial for the bemnifosbuvir/ruzasvir hepatitis C regimen met primary and secondary endpoints, showing non‑inferiority to the standard of care. The company also closed a $200 million credit facility with Hercules Capital, drawing $65 million at closing on November 6, 2026. Cash and marketable securities stood at $191.2 million at quarter‑end, and the firm expects topline results from its C‑FORWARD trial in early 2027. Management highlighted a peak U.S. sales potential of more than $700 million for the regimen.
Why it matters
The trial success positions Atea to file a U.S. NDA by mid‑2027, potentially unlocking a large hepatitis C market. The new financing gives the company runway to fund commercialization and development through mid‑2028 without diluting shareholders.
Key facts
- 1Phase 3 C‑BEYOND trial met its primary and secondary endpoints, demonstrating non‑inferiority to Epclusa (sofosbuvir/velpatasvir). rttnews.com
- 2The C‑FORWARD trial is fully enrolled with more than 880 patients and topline results are expected in early 2027. rttnews.com
- 3Atea closed a credit facility of up to $200 million with Hercules Capital and drew $65 million at closing on November 6, 2026. rttnews.com
- 4Cash, cash equivalents and marketable securities totaled $191.2 million as of September 30, 2026. rttnews.com
- 5The company projects peak U.S. net sales potential of more than $700 million for the hepatitis C regimen. investing.com
- 6Net loss narrowed to $32.16 million, or $0.40 per diluted share, versus $42.05 million, or $0.53 per share, a year earlier. rttnews.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.